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Autoreactive memory T lymphocytes are implicated in the patho-
genesis of autoimmune diseases. Here we demonstrate that
disease-associated autoreactive T cells from patients with type-1
diabetes mellitus or rheumatoid arthritis (RA) are mainly
CD4CCR7CD45RA effector memory T cells (TEM cells) with ele-
vated Kv1.3 potassium channel expression. In contrast, T cells with
other antigen specificities from these patients, or autoreactive T
cells from healthy individuals and disease controls, express low
levels of Kv1.3 and are predominantly naı¨ve or central-memory
(TCM) cells. In TEM cells, Kv1.3 traffics to the immunological synapse
during antigen presentation where it colocalizes with Kv2, SAP97,
ZIP, p56lck, and CD4. Although Kv1.3 inhibitors [ShK(L5)-amide
(SL5) and PAP1] do not prevent immunological synapse formation,
they suppress Ca2-signaling, cytokine production, and prolifera-
tion of autoantigen-specific TEM cells at pharmacologically relevant
concentrations while sparing other classes of T cells. Kv1.3 inhib-
itors ameliorate pristane-induced arthritis in rats and reduce the
incidence of experimental autoimmune diabetes in diabetes-prone
(DP-BBW) rats. Repeated dosing with Kv1.3 inhibitors in rats has
not revealed systemic toxicity. Further development of Kv1.3
blockers for autoimmune disease therapy is warranted.
effector memory T cell  rheumatoid arthritis  type-1 diabetes mellitus
T cell-mediated autoimmune diseases aff lict millions of peo-ple. Autoantigen-specific therapies would be ideal. Vaccina-
tion trials with altered myelin-peptide ligand induced a nonen-
cephalitogenic T helper 2 response in some multiple sclerosis
(MS) patients and worsened disease in others (1, 2). Disease-
modifying immunotherapies have improved the management of
autoimmune diseases; however, each of these therapies is known
to induce side effects (3–7). Consequently, there is an unmet
medical need for novel immunomodulators with different mech-
anisms of action andor adverse-effect profiles from existing
drugs. Although the frequency of autoreactive T cells in healthy
individuals and in patients with autoimmune diseases is similar
(8, 9), disease-associated autoreactive T cells are mainly co-
stimulation-independent CCR7 TEM cells, whereas autoreac-
tive T cells in healthy individuals are naı¨veTCM cells (10–16).
Therapies that selectively suppress TEM cells without affecting
other lymphoid subsets would have immense value.
Kv1.3 is one of 76 human K channel genes, and the homotet-
rameric Kv1.3 channel in T cells has distinct biophysical and
pharmacological properties (17). Kv1.3 regulates membrane
potential and Ca2 signaling in human T cells, and its expression
is increased 4- to 5-fold in activated CD4 and CD8 TEM
TEMRA cells. In contrast, human naı¨ve or TCM cells up-regulate
the calcium-activated KCa3.1 channel to regulate membrane
potential and Ca2 signaling in the activated state (10). We
previously showed that myelin-specific CD4 T cells from the
peripheral blood (PB) of MS patients and T cells in MS lesions
in postmortem brain sections were CCR7CD45RA TEM cells
with elevated Kv1.3 levels (10, 13). Furthermore, 5-methoxy-
psoralen, an analog of the Kv1.3 inhibitor PAP1, ameliorated
visual field defects, spasticity, and paraparesis in MS patients
(18), and selective in vivo Kv1.3 inhibition ameliorated disease in
a rat model for MS induced by myelin-specific CD4CD45RC
memory T cells (19, 20). In the present study we directly assayed
disease-associated autoreactive T cells from patients with rheu-
matoid arthritis (RA) or type-1 diabetes mellitus (T1DM), and
we tested whether selective Kv1.3 blockers (20, 21) alleviated
autoimmune-mediated disease in rat models of RA or T1DM
without causing toxicity.
Results and Discussion
Disease-Associated Autoreactive T Cells from Patients with RA or
T1DM Are CCR7 Kv1.3high TEM Cells. We measured Kv1.3 currents
in T cells from synovial f luid (SF) and PB of RA or nonauto-
immune osteoarthritis (OA) patients (Table 1, which is pub-
lished as supporting information on the PNAS web site). Acti-
vated T cells were patch-clamped 48 h after stimulation with
anti-CD3 Ab. RA-SF-T cells displayed higher numbers of Kv1.3
channels compared with OA-SF-T cells (P  0.0001) (Fig. 1A
and Table 2, which is published as supporting information on the
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PNAS web site). The Kv1.3high pattern was not detected in
RA-PB T cells (P  0.0001) (Fig. 1A and Table 2) because
autoreactive T cells are infrequent in the circulation and the
autoantigen-specificity of these cells is unknown, making them
difficult to identify. Immunostaining for Kv1.3 and its associated
Kv2 subunit corroborated the patch-clamp data (Fig. 1B). Flow
cytometry (FACS) demonstrated that Kv1.3high RA-SF-T cells
were predominantly CCR7 TEM cells, whereas OA-SF-T cells
and RA-PB-T cells were preponderantly CCR7 naı¨veTCM
cells (Fig. 1C). Immunostaining of synovial tissues from RA
patients revealed many Kv1.3 and CD3 T cells (Fig. 1D and
Fig. 5, which is published as supporting information on the PNAS
web site).
We next examined Kv1.3 currents in PB-T cells from T1DM
patients or controls (Table 1). Because autoantigen-specific T
cells are rare in the blood (8), we used two methods to amplify
relevant populations. First, we generated short-term antigen-
specific CD4 T cell lines (TCLs) specific for T1DM-associated
autoantigens insulin (INS; peptide 9–23) and GAD65 (peptide
555–567) or the control MS-associated autoantigen myelin basic
protein (human MBP, whole protein). TCLs were patch-clamped
48 h after the third activation with the specific autoantigen.
Second, we used phycoerythrin-tagged MHC class II tetramers
to FACS-sort CD4 T cells from HLA-DR-0401 T1DM pa-
tients that were specific for GAD65 (555–567; 557I variant
peptide) or the control antigen HA (306–318). GAD65- and
INS-specific patient T cells (TCLs and tetramer-GAD65),
regardless of disease activity or duration, expressed higher
numbers of Kv1.3 channels (1,385  210 channels per cell, n 
518 cells) compared with T cells specific for control antigens
(MBP-specific TCL, tetramer-HA, tetramer-GAD65) in
these T1DM patients (457  25 channels per cell, n  90 cells;
P  0.001) as well as in other controls (GAD65-INS-myelin-
specific-TCLs from healthy controls, GAD65-INS-specific
TCLs from MS and type-2 diabetes mellitus patients) (601  29
channels per cell, n  708 cells; P  0.001) (Fig. 2 A, C, and D,
and Fig. 6 and Tables 1, 3, and 4, which are published as
supporting information on the PNAS web site). Among the
different cohorts of T1DM patients, Kv1.3 channel numbers in
GAD65-INS-specific TCLs from recent-onset T1DM patients
(1,805  45 channels per cell, n  305 cells) were higher (P 
0.001) than in patients with longstanding T1DM (1,205 78, n
157 cells), suggesting a disappearance of Kv1.3high TEM cells
paralleling the loss of  cell antigens as the disease progresses.
In one individual with both T1DM and MS, TCLs specific for
GAD65, INS, and MBP all expressed high numbers of Kv1.3
channels (Fig. 2C). The patch-clamp data were confirmed by
immunostaining for Kv1.3 (Fig. 2 A Bottom and D Left). FACS
revealed Kv1.3high T cells to be CCR7 TEM cells (Fig. 2 B and
D). For comparison we have plotted our published data on
antigen-specific CD4 TCLs from MS patients (10). Here too,
myelin-specific TCLs were predominantly CCR7Kv1.3high TEM
Fig. 1. Kv1.3 channel expression in RA and OA T cells. (A) Kv1.3 number per
cell in RA-SF-T cells, RA-PB-T cells, and OA-SF-T cells. Most RA-SF-T cells were
CD4 cells (Fig. 5B). (B) Confocal images of Kv1.3 (green) and Kv2 (red)
staining in RA and OA T cells. (C) CCR7 expression in RA and OA T cells by FACS.
(D) Synovial tissue from RA patients stained with anti-CD3, anti-Kv1.3, or
anti-CCR7 Abs and counterstained with hematoxylineosin. Data are from five
patients studied.
Fig. 2. Kv1.3 expression in T cells specific for GAD65 (red), INS (black), or
myelin antigens (blue) from patients with T1DM, type-2 diabetes mellitus, or
MS or healthy controls. (A) Kv1.3 currents (Upper) and channel number per cell
(Lower) in activated INS-, GAD65-, and myelin-specific CD4 TCLs from new-
onset T1DM patients, healthy controls, and MS patients (10). Each data point
represents the mean  SEM from 20–50 cells from two to four TCLs from a
single donor. (B) Immunostaining for Kv1.3. (C) CCR7 expression in TCLs by
FACS. (D) Kv1.3 number per cell in TCLs from a patient with both T1DM and MS
and from patients with longstanding T1DM or type-2 diabetes mellitus. (E)
Kv1.3 channel numbers per cell and CCR7, CD45R, and Kv1.3 protein expres-
sion in CD4 T cells FACS-sorted with MHC class II tetramers loaded with
GAD65 557I peptide or HA 306–318 peptide from T1DM patients.
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cells whereas INS-GAD65-specific TCLs were CCR7Kv1.3low
naı¨veTCM cells (Fig. 2 A and B).
These results demonstrate that disease-associated autoreac-
tive T cells in T1DM, MS and RA are mainly CCR7Kv1.3high
TEM cells, and this phenotype could serve as an important
marker to distinguish autoreactive T cells between patients and
control subjects (Fig. 7, which is published as supporting infor-
mation on the PNAS web site). Because CD8 TEMTEMRA cells
also up-regulate Kv1.3 upon activation (10), we would predict
that disease-related CD8 autoreactive memory T cells (14) will
express the Kv1.3high pattern.
Specific Kv1.3 Blockers Preferentially Suppress TEM Cells from RA and
T1DM Patients. We used selective Kv1.3 blockers to discern
whether TEM cell function can be preferentially suppressed
without impacting naı¨veTCM cells in RA and T1DM patients.
Four functional parameters were measured: immunological syn-
apse (IS) formation (22), Ca2 signaling, cytokine production,
and [3H]thymidine incorporation. In human CD4 TEM cells,
Kv1.3 and its associated proteins (Fig. 3A) cocapped with CD4
(Fig. 3B), and the entire complex clustered at the IS when
GAD65-specific TEM clones were exposed to antigen-presenting
cells (APCs) loaded with GAD65 (Fig. 3C and Fig. 8, which is
published as supporting information on the PNAS web site), but
not with the irrelevant antigen MBP (Fig. 3D). SL5 (20), a
selective inhibitor of Kv1.3, neither prevented IS clustering (Fig.
3E) nor disrupted the IS once formed (Fig. 8) at a concentration
that blocks 99% of Kv1.3 channels (100 nM). These data
indicate that K efflux through Kv1.3 channels is not necessary
for IS formation or stability. IS clustering of Kv1.3 may rather
provide a mechanism for channel regulation by lck phosphory-
lation (23).
SL5 inhibited Ca2 signaling in GAD65-specific CD4 TEM
clones in a dose-dependent fashion with an IC50 200 pM (Fig.
3F), a pharmacologically relevant concentration (20). SL5 and
PAP1 (21) inhibited IL2 and IFN production by RA-SF-T cells
(mainly TEM cells) more effectively than RA-PB T cells (mainly
naı¨veTCM cells), but these Kv1.3 inhibitors were less effective in
suppressing the production of TNF- and IL4 (Fig. 3G Upper
and Fig. 9, which is published as supporting information on the
PNAS web site). SL5 also inhibited IL2 and IFN production by
GAD65-specific TEM clones from T1DM patients (Fig. 3G
Lower). SL5 was 10-fold more effective in suppressing [3H]thy-
midine incorporation by RA-SF-T cells compared with RA-
PB-T cells from the same patients (Fig. 3H Left), but when these
cell populations were activated for 48 h, rested, and restimulated,
RA-SF T cells remained exquisitely sensitive (IC50 100 pM) to
SL5 whereas RA-PB T cells were resistant (Fig. 3H Right). This
‘‘escape’’ by naı¨veTCM cells is due to up-regulation of the
KCa3.1 channel that modulates Ca2 signaling in activated
naı¨veTCM cells in place of Kv1.3 (10). A significant aspect of this
finding is that Kv1.3 blockers may have an advantage over
Fig. 3. Specific Kv1.3 blockers preferentially suppress human TEM cells. (A) Kv1.3-containing signaling complex: Kv1.3, Kv2, SAP97 (synapse-associated protein
97), ZIP (PKC -interacting protein, p56lck-associated p62 protein), p56lck, and CD4 (37). (B) Cocapping of Kv1.3 (green) with CD4 (red) in human TEM cells. (C and
D) CD4 (red) and Kv1.3 (green) staining in human GAD65-specific TEM cells exposed to APCs loaded with GAD65 557I (C) or MBP (D). (E) SL5 100 nM does not prevent
IS formation. (F) Ca2 signaling in GAD-specific CD4 TEM clones triggered by anti-CD3 plus cross-linking secondary Ab (arrow) in the absence (black) or presence
of SL5 at 0.1 nM (blue), 1 nM (green), or 100 nM (red). (G) SL5 suppression of cytokine production by RA-SF-T cells, RA-PB-T cells, and tetramer-sorted
GAD65-specific TEM clones from T1DM patients. Amounts of cytokines produced are in Fig. 9. (H Left) Anti-CD3 Ab-stimulated [3H]thymidine incorporation by
RA-PB-T cells versus RA-SF-T cells from three RA patients. (H Right) [3H]Thymidine incorporation by same two populations after they were stimulated for 48 h
with anti-CD3 Ab, rested overnight in medium, and then rechallenged with anti-CD3-Ab. (I) GAD65-specific TEM cells escape from Kv1.3 blockade as the amount
of GAD65 557I peptide increases from 10 (green) to 30 (red) to 90 (blue) gml. (J) Effect of 4-AP on TEM proliferation induced by anti-CD3 Ab. Each point
represents mean  SD of triplicates. Dotted line shows previously published data (17) on PB-T cells from healthy donors.
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current immunomodulatory therapies because naı¨ve and long-
lived TCM cells (main memory pool) would escape inhibition
while TEMTEMRA cells would be targeted. As confirmation of
specificity for TEM cells in vivo, SL5 (10 gkg per day) did not
prevent the generation of skin-homing CD3CD45RCCCR7
TEM cells or their migration to the site of a delayed-type
hypersensitivity reaction in Lewis rats, but effectively suppressed
TEM function without affecting antigen-specific IgG and IgM
responses (Fig. 10, which is published as supporting information
on the PNAS web site).
Because all CCR7 TEMTEMRA cells, regardless of antigen-
specificity, up-regulate Kv1.3 channels when activated, Kv1.3
blockers might globally suppress TEMTEMRA cells and compro-
mise the ability to respond to pathogens. However, we found that
GAD-specific CD4CCR7 TEM cells from T1DM patients
escaped SL5 suppression when the strength of antigenic stimulus
increased (Fig. 3I). This result suggests that TEM cells specific for
pathogens and vaccine antigens are likely to overcome Kv1.3
blockade when challenged by a high amount of antigen.
Kv1.3 Inhibitors Ameliorate Disease in Rat Models of RA and T1DM.
We evaluated the therapeutic potential of Kv1.3 inhibitors in rat
models of RA and T1DM. Mouse models of autoimmune disease
(e.g., NOD mice) are not suitable for evaluating the effects of
Kv1.3 blockers because the membrane potential of mouse T cells
is not regulated by KV channels (24, 25), and the K channel
expression pattern of mouse T cells, particularly repeatedly
activated cells, is different from that of human T cells (26, 27).
SL5 and PAP1 were used in the arthritis study and the experi-
mental autoimmune diabetes (EAD) study as representative
peptide and small-molecule Kv1.3 inhibitors, respectively.
We performed a treatment trial with SL5 in the pristane-
induced MHC class II-restricted chronic arthritis model (PIA) in
Dark Agouti rats (28, 29). Rats were given single daily s.c.
injections of vehicle (saline) or SL5 (100 gkg per day) at the
first sign of arthritis, and therapy was continued for 21 days. The
duration of the trial and the severity of arthritis were consistent
with published studies (28). Rats developed arthritis around day
10, and in vehicle-treated animals (n  14) disease severity
worsened continuously with time (Fig. 4A). Radiological analysis
revealed significant periostitis, erosion, and deformity, and
histopathological studies showed severe synovitis, inflammatory
cell infiltrate, and cartilage ulceration (Fig. 4 A–C). SL5-treated
rats (n  11) had significantly fewer affected joints during the
entire course of treatment (P  0.05 on days 19–34) (Fig. 4A)
and showed significant improvement in radiological and his-
topathological findings (Fig. 4 B and C). Circulating levels of
rheumatoid factor (IgG) and cartilage oligomeric matrix protein
were not significantly reduced in treated animals (Fig. 11, which
is published as supporting information on the PNAS web site).
Low-titer anti-SL5 Abs were induced in these rats (Fig. 12, which
is published as supporting information on the PNAS web site),
but it remains to be determined whether these Abs are neutral-
izing and have the potential to reduce the long-term therapeutic
effectiveness of SL5. No clinical signs of toxicity were identified
during the trial. Kv1.3 inhibitors, like TNF- receptor antago-
nists, which are the mainstay of RA therapy (30), may have to
be repeatedly administered to prevent disease progression, and
treatment may have to be initiated early in the disease. Because
Kv1.3 blockers do not effectively suppress TNF- production
(Fig. 3G), a combination of a Kv1.3 blocker and a TNF-
receptor antagonist may be more effective than either therapy
alone.
We conducted a prevention trial of PAP1 in MHC class
II-restricted DP-BBW rats, a standard model for T1DM. We
were unable to perform a treatment study because DP-BBW
rats progress to severe ketoacidosis and death with almost
complete destruction of pancreatic  cells within 1–2 days after
Fig. 4. Kv1.3 blockers ameliorate PIA and EAD in rats. (A) SL5 treatment of PIA in which vehicle-treated animals have periostitis and joint deformation. (B) X-rays
of paws. (C) Staining of joints from vehicle-treated (n 5) and SL5-treated (n 5) rats with PIA. (D) Cumulative incidence of EAD. (E) Islets immunostained for
INS (first column), CD3 (second column), CD8 (third column), and CD68 (fourth column) in vehicle-treated (Upper) and PAP1-treated (Lower) rats. (F) PAP1 reduces
 cell destruction and intraislet infiltration by T cells and macrophages on day 70. Destructioninfiltration: none, white; moderate, gray; severe, black.
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the onset of hyperglycemia (31, 32) if INS is not administered.
In contrast, NOD diabetic mice survive for weeks without
exogenous INS, and ketoacidosis is mild. DP-BBW rats daily
received vehicle (peanut oil, 3 lg, n  14) or PAP1 (n  15)
at 50 mgkg by gavage starting from 35 days of age, and
treatment was continued until day 110. The duration of our trial
is in agreement with published reports (33, 34). Vehicle-treated
rats began developing EAD at 70 days of age with 13 of 14
animals (93%) developing EAD by day 110 (Fig. 4D). In
contrast, only 7 of 15 rats treated with PAP1 (47%), which
produced pharmacologically relevant concentrations in the
blood and pancreas (Fig. 13, which is published as supporting
information on the PNAS web site), developed EAD by day 110
(P  0.02) (Fig. 4D). In comparison, anti-CD4 Ab administered
from day 7 of age to DP-BBW rats only reduced the cumulative
EAD incidence from 61% to 34% (35). In a separate group of
rats we evaluated the ability of PAP1 to prevent lymphocytic
insulitis that destroys pancreatic  cells and precedes the devel-
opment of EAD. PAP1 was administered daily from 35 to 70
days of age. In PAP1-treated rats we observed decreased in-
traislet T cell and macrophage infiltration and reduced  cell
destruction compared with vehicle-treated controls (Fig. 4E and
Fig. 14, which is published as supporting information on the
PNAS web site). Because Kv1.3 inhibitors are reported to
increase glucose uptake by mouse adipocytes by stimulating
GLUT4 translocation (36), the EAD-preventing effects of PAP1
may be via increasing peripheral INS sensitivity or via effects on
the production of the INS-sensitizing adipocyte hormone adi-
ponectin. However, neither basal nor INS-stimulated glucose
uptake or adiponectin secretion by isolated cultured rat adipo-
cytes was increased by PAP1, SL5, or margatoxin (Fig. 15, which
is published as supporting information on the PNAS web site),
indicating that PAP1 prevents EAD in DP-BBW rats via
immunomodulation. These encouraging results coupled with
results from ex vivo studies on disease-associated autoreactive T
cells from T1DM patients (Fig. 2) provide a rationale for
evaluating Kv1.3 inhibitors as a therapy for T1DM and for
preventing autoimmune destruction of HLA-matched grafted
islets in T1DM patients.
Safety Profile of Kv1.3 Inhibitors. A key issue for any long-term
therapy is the balance between efficacy and safety. Although
suppression of Kv1.3 would appear to provide a good approach
to modulate pathologic immune responses mediated by autore-
active TEM cells, Kv1.3 is also present in the central nervous
system, kidney, liver, skeletal muscle, platelets, macrophages,
testis, and osteoclasts, raising the possibility that Kv1.3 blockers
could have adverse side effects. To investigate this possibility, we
performed 28-day toxicity studies in rats with PAP1 (50 mgkg),
repeated doses being administered by gavage, and with SL5
repeatedly administered (100 gkg per day or 500 gkg per
day) by daily s.c. injections. Both blockers failed to induce any
histopathological changes in any tissue examined, including
those reported to express Kv1.3 (Table 5, which is published as
supporting information on the PNAS web site). However, SL5
produced skin irritation at the injection site (Table 6, which is
published as supporting information on the PNAS web site). The
blockers did not perceptibly alter blood cell counts or serum
chemistry parameters (Tables 5 and 6). PAP1 also failed to cause
signs of toxicity in treated DP-BBW rats during 10 weeks of
therapy. Rhesus macaques administered single doses of Kv1.3
inhibitors (PAP1, 3 mgkg i.v.; SL5, 100 gkg i.v.) did not
exhibit toxicity (A. A. Ansari, personal communication). We
previously reported that SL5 and PAP1 exhibit no perceptible in
vitro toxicity and were negative in the Ames test (20, 21), and SL5
had no effect on cardiac parameters as measured by continuous
EKG monitoring (20). The relative safety of Kv1.3 blockers may
be due in part to channel redundancy and also because Kv1.3
blockers may not inhibit Kv1.3-containing heteromultimers (e.g.,
in the CNS) with the same affinity as Kv1.3 homotetramers in T
cells. More extensive toxicity studies are necessary to confirm the
safety profile of Kv1.3 inhibitors. The dose limitations of com-
bination therapy may diminish side effects without undermining
the effective mechanism of individual therapies.
Several lines of evidence suggest that Kv1.3 inhibitors may not
increase susceptibility to infections, although this will have to be
thoroughly investigated in future. First, quinine, an antimalarial
agent, blocks Kv1.3 (IC50 14 M) (37) at concentrations found
in patients’ circulation (8–50 M) (38). Patients that have
received quinine have not exhibited an enhanced risk of infec-
tions or evidence of generalized immunosuppression (39). (Qui-
nine blocks other channels, and its toxicity profile is conse-
quently different from that of specific Kv1.3 inhibitors.) Second,
Alefacept, an immunotherapeutic that targets TEM cells (15) like
Kv1.3 inhibitors, does not increase the risk of infection in treated
psoriasis patients (4), and Alefacept-treated patients generate
normal CD4-dependent Ab responses (e.g., increases in anti-
tetanus toxoid titer after immunization) (40). These results
suggest that suppression of TEM cells by Kv1.3 inhibitors should
not increase susceptibility to infection and not compromise
immune responses to vaccination. Third, 4-aminopyridine (4-
AP), a K channel blocker used in MS therapy to augment nerve
conduction, suppressed TEM proliferation at concentrations
(IC50 8 M) (Fig. 3J) comparable to those found in treated MS
patients (cerebrospinal f luid 5 M), suggesting that the thera-
peutic effect of 4-AP may be mediated in part by TEM suppres-
sion. 4-AP is not reported to augment susceptibility to infections
or broadly immunosuppress treated MS patients. Finally, rats
housed under standard (non-specific pathogen-free) conditions
and repeatedly administered PAP1 or SL5 for 28 days did not
develop any apparent opportunistic infections.
Advantages of Kv1.3 Inhibitors. Kv1.3 blockers preferentially sup-
press autoreactive CCR7 TEM cells that arise as a consequence
of repeated autoantigen stimulation during the development of
disease, and the Kv1.3 channel, therefore, shows more specificity
for autoreactive T cells than any molecular target expressed on
all T cells. Kv1.3 blockers would have use in any autoimmune
disease in which TEM cells have been implicated. If a correlation
is found between the levels of Kv1.3high TEM cells and disease
severity, it may be feasible to use sequential short-term therapy
with Kv1.3 inhibitors when the numbers of Kv1.3high TEM cells
are high. Small-molecule Kv1.3-specific inhibitors would have
several advantages over other immunotherapeutics including
being less expensive to produce and easier to ship and store, and
their oral bioavailability and relatively short half-lives would
allow more rapid termination of therapy if adverse effects are
observed.
Materials and Methods
Patients and T Cells. Patients’ details are provided in Table 1.
Methods for generating TCLs and tetramer-sorted T cells are
provided in Supporting Text, which is published as supporting
information on the PNAS web site.
Electrophysiology. Whole-cell recordings were performed as de-
scribed (10) (see Supporting Text).
IS Formation. APCs were loaded with GAD65 557I or MBP, and
with DAPI (Molecular Probes, Eugene, OR). HLA-matched
GAD-specific TEM cell clones (41) were incubated in the absence
or the presence of 100 nM SL5 (20) for 1 h, mixed with the
antigen- and DAPI-loaded APCs, plated onto polylysine-coated
glass coverslips, fixed, and stained for confocal microscopy (see
Supporting Text).
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Measurement of Ca2 Influx. GAD-specific TEM clones (41, 42)
were loaded with 10 M Fluo-3 AM (Molecular Probes),
washed, and preincubated in the absence or the presence of
increasing amounts of SL5 for 30 min. Ca2 influx was induced
with anti-CD3 Ab (Biomeda, Foster City, CA) followed by goat
anti-mouse IgG (BD Pharmingen, San Diego, CA). Fluo-3
staining intensity was measured by FACS. At the end of each
experiment ionomycin (5 M) was added as a positive control,
followed by EGTA (5 mM) as a negative control.
Toxicity Studies. DA rats received once-daily s.c. injections of SL5
(100 or 500 gkg per day) or saline for 28 days, followed by
analysis of blood samples and histopathology assessment of
formalin-fixed organs. Similar studies were performed on PAP1-
treated Lewis rats.
Evaluating Kv1.3 Blockers in Rat Models of Disease. All experiments
were approved by the Institutional Animal Care and Use Com-
mittee at the University of California (Irvine and Davis). Female
DA rats 9–11 weeks old (Harlan-Sprague–Dawley, Indianapolis,
IN) were administered 0.3 ml of pristane (Sigma, St. Louis, MO)
by s.c. injection at the base of the tail. Rats were killed at the end
of treatment, and their joints were x-rayed or processed for
histopathology.
Female DP-BBW rats (BRM, Worcester, MA) were consid-
ered diabetic if they had a blood glucose of 200 mgdl on two
consecutive days or a single blood glucose reading 350 mgdl
accompanied by the presence of ketone bodies. Diagnosis of
EAD was confirmed for each rat at postmortem by checking for
the presence of intraislet lymphocyte infiltration and  cell
destruction. All nondiabetic animals were killed on day 110.
Statistical Analysis. Statistical analysis was carried out with the
Mann–Whitney U test or by one-way ANOVA.
Additional Details. Detailed descriptions of flow cytometry, cy-
tokine production, and [3H]thymidine incorporation can be
found in Supporting Text.
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